Search Results for: "abbvie vs amgen"

BPCIA Litigations

Pending U.S. District Court BPCIA Litigations Litigation Accused Biosimilar [status] Reference Product Complaint Filed Status/Outcome District Court Appeal Amgen v. Hospira, Nos. 18-1064, 20-561 (D. Del.) NIVESTYM (filgrastim-aafi) [approved] [launched] NEUPOGEN [litigation #4] July 18, 2018 Pending – jury trial scheduled for May 17, 2021 Immunex v. Samsung Bioepis, No….

Read More

BPCIA Litigation Roundup (Fall 2017)

Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017, Spring 2017, Summer 2017).

Read More

BPCIA Litigation Roundup (Spring 2017)

Below is our spring update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017).

Read More

Scheduling Order Entered in AbbVie v. Amgen

On Thursday, Judge Robinson entered a scheduling order in the AbbVie v. Amgen (adalimumab) case.  Among other things, the order sets a 20-day bench trial beginning November 4, 2019. The order also establishes a number of discovery and hearing deadlines that are somewhat different than those initially proposed before the…

Read More

12